Dana Webber, APRN
Family · Knoxville, TNNPI 1598264434
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $329,586 of the $498,922 with a category attached, or 66.1%. Novo Nordisk accounts for 71.9% of it on its own, with 23 other manufacturers making up the rest. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,025 payments — averaging $486.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$359K
- Lilly USA, LLC$76K
- Corcept Therapeutics$55K
- Intra-sana Laboratories$6K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$456
- Takeda Pharmaceuticals U.S.A., Inc.$380
- plus $2K from 18 others
What the payments were for
- Consulting fees$7,7962%
- Speaking & faculty fees$329,58666%
- Travel & lodging$145,04229%
- Food & beverage$16,3653%
- Education$1330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 470 | $358,945 |
| Lilly USA, LLC | 242 | $76,284 |
| Corcept Therapeutics | 122 | $54,812 |
| Intra-sana Laboratories | 19 | $5,879 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $456 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $380 |
| AbbVie | 20 | $373 |
| Currax Pharmaceuticals LLC | 25 | $351 |
| Axsome Therapeutics, Inc. | 17 | $318 |
| Tris Pharma Inc | 25 | $294 |
| Cequr Corporation | 2 | $275 |
| Paratek Pharmaceuticals, Inc. | 9 | $144 |
| Bausch Health US, LLC | 4 | $69 |
| Bayer | 4 | $61 |
| Abbott | 3 | $54 |
| Endo Pharmaceuticals Inc. | 3 | $50 |
| Pfizer | 2 | $35 |
| Exact Sciences | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Nevro Corp. | 1 | $19 |
| Halozyme Inc | 1 | $19 |
| Alkermes, Inc. | 1 | $18 |
| Inogen, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$204,724
- Saxenda$149,096
- MOUNJARO$56,513
- Korlym$52,997
- Reltone 200 Mg$5,118
- GLYCATE$5,118
- Reltone 400 Mg$5,118
- CeQur Simplicity$275
How this compares
$498,922 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 177 | $201,948 |
| LinzessLinaclotide | 15 | $23,483 |
| OzempicSemaglutide | 12 | $23,100 |
| JardianceEmpagliflozin | 13 | $11,294 |
| Ondansetron OdtOndansetron | 39 | $997 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $609 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $423 |
| Amitriptyline Hcl | 11 | $307 |
| Liothyronine Sodium | 13 | $294 |
| Gabapentin | 34 | $292 |
| Hydroxyzine Hcl | 24 | $245 |
| Levothyroxine Sodium | 47 | $190 |
| Tizanidine Hcl | 17 | $186 |
| Omeprazole | 20 | $142 |
| Sertraline Hcl | 14 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $76,284 | $201,948177 claims |
| AbbVieLinzess | $373 | $23,48315 claims |
| Novo NordiskOzempic | $358,945 | $23,10012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Knoxville
- Tiffany SipeKnoxville$87K
- Ashley BonnellKnoxville$49K
- Stacey MaltmanKnoxville$34K
- Katherine JohnsonKnoxville$32K
- Ashley BellKnoxville$22K
- Carol HawkinsKnoxville$22K
- Mina FarrarKnoxville$21K
- Amy AllenKnoxville$21K
- Sarah HarderKnoxville$19K
- Stacy BrownMt Juliet$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.